person · Reporting owner

Sherman Jeffrey Scott

Disclosed activity across 3 companies

Tapewire entity: 65027
SEC CIK: 0001463145

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
NEOGENOMICS INCNEO · Entity 2096	Chief Financial Officer	February 21, 2026	February 24, 2026
Privia Health Group, Inc.PRVA · Entity 1532	EVP, CFO and CAO	January 05, 2022	January 07, 2022

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

NEOGENOMICS INC

Report date February 21, 2026 · Filed February 24, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	218,986	Reported balance After 2026-02-21 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2026-02-21 · Exercise / conversion · Acquired 42,158 · Balance 218,986 F1: Each restricted stock unit is the economic equivalent of one share of NeoGenomics common stock and is converted into common stock upon vesting. F2: This balance includes 434 shares that were acquired pursuant to NeoGenomics' Employee Stock Purchase Plan. The shares were acquired in transactions exempt from Section 16b-3.
Common StockSEC Table I · non-derivative	Direct	208,257	Reported balance After 2026-02-21 transaction · row 2 Account or security details depend on footnotes; rows are not merged. 1 source row Row 2 · 2026-02-21 · Tax withholding · Disposed 10,729 · Balance 208,257 F3: Disposition of shares was in connection with the Issuer's withholding of common stock to satisfy tax withholding obligations related to the issuance of common stock upon release of restricted stock units.
Common StockSEC Table I · non-derivative	Direct	223,792	Reported balance After 2026-02-23 transaction · row 3 Account or security details depend on footnotes; rows are not merged. 1 source row Row 3 · 2026-02-23 · Exercise / conversion · Acquired 15,535 · Balance 223,792 F1: Each restricted stock unit is the economic equivalent of one share of NeoGenomics common stock and is converted into common stock upon vesting.
Common StockSEC Table I · non-derivative	Direct	220,009	Reported balance After 2026-02-23 transaction · row 4 Account or security details depend on footnotes; rows are not merged. 1 source row Row 4 · 2026-02-23 · Tax withholding · Disposed 3,783 · Balance 220,009 F3: Disposition of shares was in connection with the Issuer's withholding of common stock to satisfy tax withholding obligations related to the issuance of common stock upon release of restricted stock units.
Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	84,318	Reported balance After 2026-02-21 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2026-02-21 · Exercise / conversion · Disposed 42,158 · Balance 84,318 F4: On February 21, 2025, Mr. Sherman was granted 126,476 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date. F5: Once vested, the shares of common stock are not subject to expiration.
Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	15,536	Reported balance After 2026-02-23 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2026-02-23 · Exercise / conversion · Disposed 15,535 · Balance 15,536 F6: On February 23, 2024, Mr. Sherman was granted 46,606 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date. F5: Once vested, the shares of common stock are not subject to expiration.
Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	13,006	Reported balance Holding disclosure · report date 2026-02-21 · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · Balance 13,006 F9: On May 11, 2023, Mr. Sherman was granted 39,016 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date. F5: Once vested, the shares of common stock are not subject to expiration.
Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	59,382	Reported balance Holding disclosure · report date 2026-02-21 · row 13 Instrument identity requires review; Table II rows are not merged. 1 source row Row 13 · Balance 59,382 F5: Once vested, the shares of common stock are not subject to expiration.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.62 · Expires 2029-12-05	Direct	249,169	Reported balance Holding disclosure · report date 2026-02-21 · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · Balance 249,169 F7: On December 5, 2022, Mr. Sherman was granted 249,169 stock options. The options vest ratably over four years with the first tranche vesting on December 7, 2023.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.65 · Expires 2030-05-11	Direct	73,016	Reported balance Holding disclosure · report date 2026-02-21 · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · Balance 73,016 F8: On May 11, 2023, Mr. Sherman was granted 73,016 stock options. The options vest ratably over the first three anniversary dates of the grant date.
Performance Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	39,016	Reported balance Holding disclosure · report date 2026-02-21 · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · Balance 39,016 F10: On May 11, 2023, Mr. Sherman was granted 39,016 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is 58,524. The number of performance stock units that may vest is based on the achievement of certain share growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period at the applicable measurement dates, subject to continued service with the Company. F5: Once vested, the shares of common stock are not subject to expiration.
Performance Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	46,606	Reported balance Holding disclosure · report date 2026-02-21 · row 12 Instrument identity requires review; Table II rows are not merged. 1 source row Row 12 · Balance 46,606 F12: On February 23, 2024, Mr. Sherman was granted 46,606 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is 69,910. 50% of the number of performance stock units that may vest is based on the achievements of certain share growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period at the applicable measurement dates, subject to continued service with the Company. 50% of the number of performance stock units that may vest is based on the achievement of certain revenue growth goals based on the achievement of the cumulative fiscal year revenue goal at the applicable measurement amounts, subject to continued service with the Company. F5: Once vested, the shares of common stock are not subject to expiration.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.45 · Expires 2034-02-23	Direct	77,913	Reported balance Holding disclosure · report date 2026-02-21 · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · Balance 77,913 F11: On February 23, 2024, Mr. Sherman was granted 77,913 stock options. The options vest ratably over the first three anniversary dates of the grant date.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.05 · Expires 2035-02-21	Direct	214,900	Reported balance Holding disclosure · report date 2026-02-21 · row 14 Instrument identity requires review; Table II rows are not merged. 1 source row Row 14 · Balance 214,900 F13: This stock option was granted as a premium-price stock option. To calculate the premium exercise price we used the closing price on February 20, 2025 and multiplied by 110%. F14: On February 21, 2025, Mr. Sherman was granted 214,900 stock options. The options vest ratably over the first three anniversary dates of the grant date.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit is the economic equivalent of one share of NeoGenomics common stock and is converted into common stock upon vesting.

F2: This balance includes 434 shares that were acquired pursuant to NeoGenomics' Employee Stock Purchase Plan. The shares were acquired in transactions exempt from Section 16b-3.

F3: Disposition of shares was in connection with the Issuer's withholding of common stock to satisfy tax withholding obligations related to the issuance of common stock upon release of restricted stock units.

F4: On February 21, 2025, Mr. Sherman was granted 126,476 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date.

F5: Once vested, the shares of common stock are not subject to expiration.

F6: On February 23, 2024, Mr. Sherman was granted 46,606 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date.

F7: On December 5, 2022, Mr. Sherman was granted 249,169 stock options. The options vest ratably over four years with the first tranche vesting on December 7, 2023.

F8: On May 11, 2023, Mr. Sherman was granted 73,016 stock options. The options vest ratably over the first three anniversary dates of the grant date.

F9: On May 11, 2023, Mr. Sherman was granted 39,016 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date.

F10: On May 11, 2023, Mr. Sherman was granted 39,016 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is 58,524. The number of performance stock units that may vest is based on the achievement of certain share growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period at the applicable measurement dates, subject to continued service with the Company.

F11: On February 23, 2024, Mr. Sherman was granted 77,913 stock options. The options vest ratably over the first three anniversary dates of the grant date.

F12: On February 23, 2024, Mr. Sherman was granted 46,606 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is 69,910. 50% of the number of performance stock units that may vest is based on the achievements of certain share growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period at the applicable measurement dates, subject to continued service with the Company. 50% of the number of performance stock units that may vest is based on the achievement of certain revenue growth goals based on the achievement of the cumulative fiscal year revenue goal at the applicable measurement amounts, subject to continued service with the Company.

F13: This stock option was granted as a premium-price stock option. To calculate the premium exercise price we used the closing price on February 20, 2025 and multiplied by 110%.

F14: On February 21, 2025, Mr. Sherman was granted 214,900 stock options. The options vest ratably over the first three anniversary dates of the grant date.

Privia Health Group, Inc.

Report date January 05, 2022 · Filed January 07, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock, $0.01 par value per shareSEC Table I · non-derivative	Direct	61,307	Reported balance After 2022-01-05 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2022-01-05 · Grant · Acquired 61,307 · Balance 61,307 F1: Represents restricted stock units granted under the Issuer's 2021 Omnibus Incentive Plan that will vest in substantially equal annual installments on the first, second, third and fourth anniversaries of the grant date.
Stock Option (Right to Purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $25.69 · Expires 2032-01-05	Direct	235,128	Reported balance After 2022-01-05 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2022-01-05 · Grant · Acquired 235,128 · Balance 235,128 F2: Represents options granted under the Issuer's 2021 Omnibus Incentive Plan that will vest in substantially equal annual installments on the first, second, third and fourth anniversaries of the grant date.

Filing footnotes · ownership attribution and instrument terms

F1: Represents restricted stock units granted under the Issuer's 2021 Omnibus Incentive Plan that will vest in substantially equal annual installments on the first, second, third and fourth anniversaries of the grant date.

F2: Represents options granted under the Issuer's 2021 Omnibus Incentive Plan that will vest in substantially equal annual installments on the first, second, third and fourth anniversaries of the grant date.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

HMS HOLDINGS CORP

Report date April 01, 2021 · Filed April 01, 2021

Section 16 reporting ended · disclosed 2021-04-01. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2021-04-01 transaction · row 1 1 source row Row 1 · 2021-04-01 · Disposition to issuer · Disposed 200,630 · Balance 0 F1: On April 1, 2021, pursuant to that certain Agreement and Plan of Merger, dated as of December 20, 2020 (the "Merger Agreement"), by and among the Issuer, Gainwell Acquisition Corp. ("Gainwell"), Mustang Merger Sub, Inc. ("Merger Sub") and Gainwell Intermediate Holding Corp., Merger Sub merged with and into the Issuer with the Issuer surviving as a wholly owned subsidiary of IRC (the "Merger"). Upon consummation of the Merger (the "Effective Time"), each share of common stock of the Issuer was cancelled and converted into the right to receive $37.00 per share in cash (the "Per Share Merger Consideration"). In addition, each unvested restricted stock unit automatically vested and was converted in the right to receive the Per Share Merger Consideration.
Common StockSEC Table I · non-derivative	IndirectBy Family Trust	Reported balance After 2021-04-01 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2021-04-01 · Disposition to issuer · Disposed 10,760 · Balance 0 F1: On April 1, 2021, pursuant to that certain Agreement and Plan of Merger, dated as of December 20, 2020 (the "Merger Agreement"), by and among the Issuer, Gainwell Acquisition Corp. ("Gainwell"), Mustang Merger Sub, Inc. ("Merger Sub") and Gainwell Intermediate Holding Corp., Merger Sub merged with and into the Issuer with the Issuer surviving as a wholly owned subsidiary of IRC (the "Merger"). Upon consummation of the Merger (the "Effective Time"), each share of common stock of the Issuer was cancelled and converted into the right to receive $37.00 per share in cash (the "Per Share Merger Consideration"). In addition, each unvested restricted stock unit automatically vested and was converted in the right to receive the Per Share Merger Consideration.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.04 · Expires 2027-06-09	Direct	Reported balance After 2021-04-01 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2021-04-01 · Disposition to issuer · Disposed 109,961 · Balance 0 F2: Pursuant to the procedures set forth in the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock with a per share exercise price that is less than the Per Share Merger Consideration that is outstanding and unexercised, was cancelled and converted into the right to receive a cash payment equal to the product of (x) the Per Share Merger Consideration, net of the applicable per share exercise price and (y) the aggregate number of shares of Common Stock subject to the option, less applicable withholding taxes or other amounts required by law.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.48 · Expires 2028-03-02	Direct	Reported balance After 2021-04-01 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2021-04-01 · Disposition to issuer · Disposed 117,130 · Balance 0 F2: Pursuant to the procedures set forth in the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock with a per share exercise price that is less than the Per Share Merger Consideration that is outstanding and unexercised, was cancelled and converted into the right to receive a cash payment equal to the product of (x) the Per Share Merger Consideration, net of the applicable per share exercise price and (y) the aggregate number of shares of Common Stock subject to the option, less applicable withholding taxes or other amounts required by law.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $27.34 · Expires 2030-02-27	Direct	Reported balance After 2021-04-01 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2021-04-01 · Disposition to issuer · Disposed 112,360 · Balance 0 F2: Pursuant to the procedures set forth in the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock with a per share exercise price that is less than the Per Share Merger Consideration that is outstanding and unexercised, was cancelled and converted into the right to receive a cash payment equal to the product of (x) the Per Share Merger Consideration, net of the applicable per share exercise price and (y) the aggregate number of shares of Common Stock subject to the option, less applicable withholding taxes or other amounts required by law.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $39.63 · Expires 2029-02-28	Direct	Reported balance After 2021-04-01 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2021-04-01 · Disposition to issuer · Disposed 65,265 · Balance 0 F3: Pursuant to the procedures set forth in the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock with a per share exercise price that is equal or greater than the Per Share Merger Consideration, whether vested or unvested, was cancelled for no consideration.

Filing footnotes · ownership attribution and instrument terms

F1: On April 1, 2021, pursuant to that certain Agreement and Plan of Merger, dated as of December 20, 2020 (the "Merger Agreement"), by and among the Issuer, Gainwell Acquisition Corp. ("Gainwell"), Mustang Merger Sub, Inc. ("Merger Sub") and Gainwell Intermediate Holding Corp., Merger Sub merged with and into the Issuer with the Issuer surviving as a wholly owned subsidiary of IRC (the "Merger"). Upon consummation of the Merger (the "Effective Time"), each share of common stock of the Issuer was cancelled and converted into the right to receive $37.00 per share in cash (the "Per Share Merger Consideration"). In addition, each unvested restricted stock unit automatically vested and was converted in the right to receive the Per Share Merger Consideration.

F2: Pursuant to the procedures set forth in the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock with a per share exercise price that is less than the Per Share Merger Consideration that is outstanding and unexercised, was cancelled and converted into the right to receive a cash payment equal to the product of (x) the Per Share Merger Consideration, net of the applicable per share exercise price and (y) the aggregate number of shares of Common Stock subject to the option, less applicable withholding taxes or other amounts required by law.

F3: Pursuant to the procedures set forth in the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock with a per share exercise price that is equal or greater than the Per Share Merger Consideration, whether vested or unvested, was cancelled for no consideration.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
February 23, 2026 Filed Feb 24, 2026 21:15 UTC	NEOGENOMICS INC NEO · Entity 2096	Exercise / conversionRestricted Stock Unit · Derivative	15,535	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001628280-26-011099 · wk-form4_1771967703.xml · derivative · entry 6 Sherman Jeffrey Scott · CIK 0001463145 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,536 Underlying: Common Stock · 15,535 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: On February 23, 2024, Mr. Sherman was granted 46,606 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date. F5 · derivative.expiration_date: Once vested, the shares of common stock are not subject to expiration. Read SEC document
February 23, 2026 Filed Feb 24, 2026 21:15 UTC	NEOGENOMICS INC NEO · Entity 2096	Tax withholdingCommon Stock	3,783	$0.00	$0.00	Disclosure SEC source: 0001628280-26-011099 · wk-form4_1771967703.xml · nonDerivative · entry 4 Sherman Jeffrey Scott · CIK 0001463145 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 220,009 F3 · shares: Disposition of shares was in connection with the Issuer's withholding of common stock to satisfy tax withholding obligations related to the issuance of common stock upon release of restricted stock units. Read SEC document
February 23, 2026 Filed Feb 24, 2026 21:15 UTC	NEOGENOMICS INC NEO · Entity 2096	Exercise / conversionCommon Stock	15,535	$0.00	$0.00	Disclosure SEC source: 0001628280-26-011099 · wk-form4_1771967703.xml · nonDerivative · entry 3 Sherman Jeffrey Scott · CIK 0001463145 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 223,792 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit is the economic equivalent of one share of NeoGenomics common stock and is converted into common stock upon vesting. Read SEC document
February 21, 2026 Filed Feb 24, 2026 21:15 UTC	NEOGENOMICS INC NEO · Entity 2096	Exercise / conversionRestricted Stock Unit · Derivative	42,158	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001628280-26-011099 · wk-form4_1771967703.xml · derivative · entry 5 Sherman Jeffrey Scott · CIK 0001463145 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,318 Underlying: Common Stock · 42,158 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: On February 21, 2025, Mr. Sherman was granted 126,476 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date. F5 · derivative.expiration_date: Once vested, the shares of common stock are not subject to expiration. Read SEC document
February 21, 2026 Filed Feb 24, 2026 21:15 UTC	NEOGENOMICS INC NEO · Entity 2096	Tax withholdingCommon Stock	10,729	$0.00	$0.00	Disclosure SEC source: 0001628280-26-011099 · wk-form4_1771967703.xml · nonDerivative · entry 2 Sherman Jeffrey Scott · CIK 0001463145 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 208,257 F3 · shares: Disposition of shares was in connection with the Issuer's withholding of common stock to satisfy tax withholding obligations related to the issuance of common stock upon release of restricted stock units. Read SEC document
February 21, 2026 Filed Feb 24, 2026 21:15 UTC	NEOGENOMICS INC NEO · Entity 2096	Exercise / conversionCommon Stock	42,158	$0.00	$0.00	Disclosure SEC source: 0001628280-26-011099 · wk-form4_1771967703.xml · nonDerivative · entry 1 Sherman Jeffrey Scott · CIK 0001463145 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 218,986 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit is the economic equivalent of one share of NeoGenomics common stock and is converted into common stock upon vesting. F2 · balance_after: This balance includes 434 shares that were acquired pursuant to NeoGenomics' Employee Stock Purchase Plan. The shares were acquired in transactions exempt from Section 16b-3. Read SEC document
December 07, 2025 Filed Dec 9, 2025 21:16 UTC	NEOGENOMICS INC NEO · Entity 2096	Tax withholdingCommon Stock	11,938	$0.00	$0.00	Disclosure SEC source: 0001628280-25-056080 · wk-form4_1765314983.xml · nonDerivative · entry 1 Sherman Jeffrey Scott · CIK 0001463145 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 176,394 F1 · shares: Shares surrendered to NeoGenomics, Inc. for retirement to satisfy the tax obligations in connection with the December 1, 2025 vesting of restricted stock. Read SEC document
August 06, 2025 Filed Aug 6, 2025 20:07 UTC	NEOGENOMICS INC NEO · Entity 2096	PurchaseCommon Stock	20,000	$5.62	$112,322.00	Disclosure SEC source: 0001628280-25-038324 · wk-form4_1754510873.xml · nonDerivative · entry 1 Sherman Jeffrey Scott · CIK 0001463145 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 188,332 Read SEC document
May 11, 2025 Filed May 13, 2025 20:06 UTC	NEOGENOMICS INC NEO · Entity 2096	Exercise / conversionRestricted Stock Unit · Derivative	13,005	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001077183-25-000105 · wk-form4_1747166756.xml · derivative · entry 3 Sherman Jeffrey Scott · CIK 0001463145 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,006 Underlying: Common Stock · 13,005 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: On May 11, 2023, Mr. Sherman was granted 39,016 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date. F4 · derivative.expiration_date: Once vested, the shares of common stock are not subject to expiration. Read SEC document
May 11, 2025 Filed May 13, 2025 20:06 UTC	NEOGENOMICS INC NEO · Entity 2096	Tax withholdingCommon Stock	3,167	$0.00	$0.00	Disclosure SEC source: 0001077183-25-000105 · wk-form4_1747166756.xml · nonDerivative · entry 2 Sherman Jeffrey Scott · CIK 0001463145 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 168,332 F2 · shares: Disposition of shares was in connection with the Issuer's withholding of common stock to satisfy tax withholding obligations related to the issuance of common stock upon release of restricted stock units. Read SEC document
May 11, 2025 Filed May 13, 2025 20:06 UTC	NEOGENOMICS INC NEO · Entity 2096	Exercise / conversionCommon Stock	13,005	$0.00	$0.00	Disclosure SEC source: 0001077183-25-000105 · wk-form4_1747166756.xml · nonDerivative · entry 1 Sherman Jeffrey Scott · CIK 0001463145 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 171,499 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit is the economic equivalent of NeoGenomics common stock and is converted into common stock upon vesting. Read SEC document
May 02, 2025 Filed May 6, 2025 20:08 UTC	NEOGENOMICS INC NEO · Entity 2096	PurchaseCommon Stock	20,000	$7.51	$150,104.00	Disclosure SEC source: 0001077183-25-000090 · wk-form4_1746562124.xml · nonDerivative · entry 1 Sherman Jeffrey Scott · CIK 0001463145 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 158,494 F1 · balance_after: This balance includes 1,430 shares that were acquired pursuant to NeoGenomics' Employee Stock Purchase Plan (ESPP) since the date of the reporting person's last filing. The shares were acquired in transactions exempt from Section 16b-3. Read SEC document
February 23, 2025 Filed Feb 25, 2025 21:38 UTC	NEOGENOMICS INC NEO · Entity 2096	Exercise / conversionRestricted Stock Unit · Derivative	15,535	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001077183-25-000040 · wk-form4_1740519501.xml · derivative · entry 5 Sherman Jeffrey Scott · CIK 0001463145 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,071 Underlying: Common Stock · 15,535 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: On February 23, 2024, Mr. Sherman was granted 46,606 restricted stock units. These restricted stock units vest ratably over the first three anniversary dates of the grant date. F7 · derivative.expiration_date: Once vested, the shares of common stock are not subject to expiration. Read SEC document
February 23, 2025 Filed Feb 25, 2025 21:38 UTC	NEOGENOMICS INC NEO · Entity 2096	Tax withholdingCommon Stock	4,207	$0.00	$0.00	Disclosure SEC source: 0001077183-25-000040 · wk-form4_1740519501.xml · nonDerivative · entry 2 Sherman Jeffrey Scott · CIK 0001463145 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 137,064 F3 · shares: Disposition of shares was in connection with the Issuer's withholding of common stock to satisfy tax withholding obligations related to the issuance of common stock upon release of restricted stock units. Read SEC document
February 23, 2025 Filed Feb 25, 2025 21:38 UTC	NEOGENOMICS INC NEO · Entity 2096	Exercise / conversionCommon Stock	15,535	$0.00	$0.00	Disclosure SEC source: 0001077183-25-000040 · wk-form4_1740519501.xml · nonDerivative · entry 1 Sherman Jeffrey Scott · CIK 0001463145 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 141,271 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit is the economic equivalent of one share of NeoGenomics common stock and is converted into common stock upon vesting. F2 · balance_after: This balance includes 1,982 shares that were acquired pursuant to NeoGenomics' Employee Stock Purchase Plan (ESPP). The shares were acquired in transactions exempt from Section 16b-3. Read SEC document
February 21, 2025 Filed Feb 25, 2025 21:38 UTC	NEOGENOMICS INC NEO · Entity 2096	GrantRestricted Stock Unit · Derivative	126,476	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001077183-25-000040 · wk-form4_1740519501.xml · derivative · entry 4 Sherman Jeffrey Scott · CIK 0001463145 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 126,476 Underlying: Common Stock · 126,476 shares Expires not disclosed F6 · derivative.exercise_date: On February 21, 2025, Mr. Sherman was granted 126,476 restricted stock units. These restricted stock units vest ratably over the first three anniversary dates of the grant date. F7 · derivative.expiration_date: Once vested, the shares of common stock are not subject to expiration. Read SEC document
February 21, 2025 Filed Feb 25, 2025 21:38 UTC	NEOGENOMICS INC NEO · Entity 2096	GrantStock Option (Right to Buy) · Derivative	214,900	$0.00 Strike: $13.05	$0.00	Disclosure SEC source: 0001077183-25-000040 · wk-form4_1740519501.xml · derivative · entry 3 Sherman Jeffrey Scott · CIK 0001463145 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 214,900 Underlying: Common Stock · 214,900 shares Expires 2035-02-21 F4 · derivative.exercise_price: This stock option was granted as a premium-price stock option. To calculate the premium exercise price we used the closing price on February 20, 2025 and multiplied by 110%. F5 · derivative.exercise_date: On February 21, 2025, Mr. Sherman was granted 214,900 stock options. These options vest ratably over the first three anniversary dates of the grant date. Read SEC document
January 14, 2025 Filed Jan 16, 2025 21:13 UTC	NEOGENOMICS INC NEO · Entity 2096	GrantRestricted Stock Unit · Derivative	59,382	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001077183-25-000020 · wk-form4_1737062006.xml · derivative · entry 2 Sherman Jeffrey Scott · CIK 0001463145 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,382 Underlying: Common Stock · 59,382 shares Expires not disclosed F1 · derivative.expiration_date: Once vested, the shares of common stock are not subject to expiration. Read SEC document
December 07, 2024 Filed Dec 10, 2024 21:09 UTC	NEOGENOMICS INC NEO · Entity 2096	Tax withholdingCommon Stock	11,746	$0.00	$0.00	Disclosure SEC source: 0001077183-24-000172 · wk-form4_1733864943.xml · nonDerivative · entry 1 Sherman Jeffrey Scott · CIK 0001463145 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 123,754 F1 · shares: Shares surrendered to NeoGenomics, Inc. for retirement to satisfy the tax obligations in connection with the December 7, 2024 vesting of restricted stock. Read SEC document
May 11, 2024 Filed May 15, 2024 01:38 UTC	NEOGENOMICS INC NEO · Entity 2096	Exercise / conversionRestricted Stock Unit · Derivative	13,005	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001077183-24-000072 · wk-form4_1715737091.xml · derivative · entry 4 Sherman Jeffrey Scott · CIK 0001463145 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,011 Underlying: Common Stock · 13,005 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: On May 11, 2023, Mr. Sherman was granted 39,016 restricted stock units. These restricted stock units vest ratably over the first three anniversary dates of the grant date. F4 · derivative.expiration_date: Once vested, the shares of common stock are not subject to expiration. Read SEC document
May 11, 2024 Filed May 15, 2024 01:38 UTC	NEOGENOMICS INC NEO · Entity 2096	Exercise / conversionCommon Stock	13,005	$0.00	$0.00	Disclosure SEC source: 0001077183-24-000072 · wk-form4_1715737091.xml · nonDerivative · entry 3 Sherman Jeffrey Scott · CIK 0001463145 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 148,505 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
May 11, 2024 Filed May 15, 2024 01:38 UTC	NEOGENOMICS INC NEO · Entity 2096	Tax withholdingCommon Stock	3,167	$14.86	$47,061.62	Disclosure SEC source: 0001077183-24-000072 · wk-form4_1715737091.xml · nonDerivative · entry 2 Sherman Jeffrey Scott · CIK 0001463145 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 135,500 F2 · shares: Disposition of shares was in connection with the Issuer's withholding of common stock to satisfy tax withholding obligations related to the issuance of common stock upon release of restricted stock units. Read SEC document
May 11, 2024 Filed May 15, 2024 01:38 UTC	NEOGENOMICS INC NEO · Entity 2096	Exercise / conversionCommon Stock	13,005	$0.00	$0.00	Disclosure SEC source: 0001077183-24-000072 · wk-form4_1715737091.xml · nonDerivative · entry 1 Sherman Jeffrey Scott · CIK 0001463145 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 138,667 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit is the economic equivalent of one share of NeoGenomics common stock and is converted into common stock upon vesting. Read SEC document
May 11, 2024 Filed Dec 4, 2024 21:10 UTC Amendment	NEOGENOMICS INC NEO · Entity 2096	Exercise / conversionRestricted Stock Unit · Derivative	13,005	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001077183-24-000169 · wk-form4a_1733346601.xml · derivative · entry 3 Sherman Jeffrey Scott · CIK 0001463145 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,011 Underlying: Common Stock · 13,005 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: On May 11, 2023, Mr. Sherman was granted 39,016 restricted stock units. These restricted stock units vest ratably over the first three anniversary dates of the grant date. F5 · derivative.expiration_date: Once vested, the shares of common stock are not subject to expiration. Read SEC document
May 11, 2024 Filed Dec 4, 2024 21:10 UTC Amendment	NEOGENOMICS INC NEO · Entity 2096	Tax withholdingCommon Stock	3,167	$14.86	$47,061.62	Disclosure SEC source: 0001077183-24-000169 · wk-form4a_1733346601.xml · nonDerivative · entry 2 Sherman Jeffrey Scott · CIK 0001463145 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 135,500 F2 · shares: Disposition of shares was in connection with the Issuer's withholding of common stock to satisfy tax withholding obligations related to the issuance of common stock upon release of restricted stock units. F3 · balance_after: On May 14, 2024, the reporting person filed a Form 4 which inadvertently reported the number of shares of common stock received upon the vesting of certain of his RSUs twice. In fact, as reported in this amendment, the reporting person directly owned 135,500 shares of common stock after the vesting of 13,005 RSUs and reported withholding. Read SEC document
May 11, 2024 Filed Dec 4, 2024 21:10 UTC Amendment	NEOGENOMICS INC NEO · Entity 2096	Exercise / conversionCommon Stock	13,005	$0.00	$0.00	Disclosure SEC source: 0001077183-24-000169 · wk-form4a_1733346601.xml · nonDerivative · entry 1 Sherman Jeffrey Scott · CIK 0001463145 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 138,667 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit is the economic equivalent of one share of NeoGenomics common stock and is converted into common stock upon vesting. Read SEC document
February 23, 2024 Filed Feb 27, 2024 21:28 UTC	NEOGENOMICS INC NEO · Entity 2096	GrantPerformance Stock Unit · Derivative	46,606	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001077183-24-000029 · wk-form4_1709069299.xml · derivative · entry 8 Sherman Jeffrey Scott · CIK 0001463145 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,606 Underlying: Common Stock · 46,606 shares Expires not disclosed F8 · derivative.exercise_date: On February 23, 2024, Mr. Sherman was granted 46,606 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is 69,910. 50% of the number of performance stock units that may vest is based on the achievements of certain share growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period at the applicable measurement dates, subject to continued service with the Company. 50% of the number of performance stock units that may vest is based on the achievement of certain revenue growth goals based on the achievement of the cumulative fiscal year revenue goal at the applicable measurement amounts, subject to continued service with the Company. F4 · derivative.expiration_date: Once vested, the shares of common stock are not subject to expiration. Read SEC document
February 23, 2024 Filed Feb 27, 2024 21:28 UTC	NEOGENOMICS INC NEO · Entity 2096	GrantRestricted Stock Unit · Derivative	46,606	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001077183-24-000029 · wk-form4_1709069299.xml · derivative · entry 7 Sherman Jeffrey Scott · CIK 0001463145 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,606 Underlying: Common Stock · 46,606 shares Expires not disclosed F7 · derivative.exercise_date: On February 23, 2024, Mr. Sherman was granted 46,606 restricted stock units. These restricted stock units vest ratably over the first three anniversary dates of the grant date. F4 · derivative.expiration_date: Once vested, the shares of common stock are not subject to expiration. Read SEC document
February 23, 2024 Filed Feb 27, 2024 21:28 UTC	NEOGENOMICS INC NEO · Entity 2096	GrantStock Option (Right to Buy) · Derivative	77,913	$0.00 Strike: $16.45	$0.00	Disclosure SEC source: 0001077183-24-000029 · wk-form4_1709069299.xml · derivative · entry 6 Sherman Jeffrey Scott · CIK 0001463145 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,913 Underlying: Common Stock · 77,913 shares Expires 2034-02-23 F6 · derivative.exercise_date: On February 23, 2024, Mr. Sherman was granted 77,913 stock options. These options vest ratably over the first three anniversary dates of the grant date. Read SEC document
December 07, 2023 Filed Dec 12, 2023 00:54 UTC	NEOGENOMICS INC NEO · Entity 2096	Tax withholdingCommon Stock	8,147	$0.00	$0.00	Disclosure SEC source: 0001077183-23-000144 · wk-form4_1702342485.xml · nonDerivative · entry 1 Sherman Jeffrey Scott · CIK 0001463145 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,662 F1 · shares: Shares surrendered to NeoGenomics Inc. for retirement to satisfy the tax obligations in connection with the December 7, 2023 vesting of restricted stock. Read SEC document
May 11, 2023 Filed May 15, 2023 21:06 UTC	NEOGENOMICS INC NEO · Entity 2096	GrantPerformance Stock Unit · Derivative	39,016	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001077183-23-000053 · wf-form4_168418478078441.xml · derivative · entry 5 Sherman Jeffrey Scott · CIK 0001463145 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,016 Underlying: Common Stock · 39,016 shares Expires not disclosed F5 · derivative.exercise_date: On May 11, 2023, Mr. Sherman was granted 39,016 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is 58,524. The number of performance stock units that may vest is based on the achievement of certain share growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period at the applicable measurement dates, subject to continued service with the Company. F4 · derivative.expiration_date: Once vested, the shares of common stock are not subject to expiration. Read SEC document
May 11, 2023 Filed May 15, 2023 21:06 UTC	NEOGENOMICS INC NEO · Entity 2096	GrantRestricted Stock Unit · Derivative	39,016	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001077183-23-000053 · wf-form4_168418478078441.xml · derivative · entry 4 Sherman Jeffrey Scott · CIK 0001463145 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,016 Underlying: Common Stock · 39,016 shares Expires not disclosed F3 · derivative.exercise_date: On May 11, 2023, Mr. Sherman was granted 39,016 restricted stock units. These restricted stock units vest ratably over the first three anniversary dates of the grant date. F4 · derivative.expiration_date: Once vested, the shares of common stock are not subject to expiration. Read SEC document
May 11, 2023 Filed May 15, 2023 21:06 UTC	NEOGENOMICS INC NEO · Entity 2096	GrantStock Option (Right to Buy) · Derivative	73,016	$0.00 Strike: $19.65	$0.00	Disclosure SEC source: 0001077183-23-000053 · wf-form4_168418478078441.xml · derivative · entry 3 Sherman Jeffrey Scott · CIK 0001463145 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,016 Underlying: Common Stock · 73,016 shares Expires 2030-05-11 F2 · derivative.exercise_date: On May 11, 2023, Mr. Sherman was granted 73,016 stock options. These options vest ratably over the first three anniversary dates of the grant date. Read SEC document
December 05, 2022 Filed Dec 8, 2022 01:47 UTC	NEOGENOMICS INC NEO · Entity 2096	GrantStock Option (Right to Buy) · Derivative	249,169	$0.00 Strike: $11.62	$0.00	Disclosure SEC source: 0001077183-22-000202 · wf-form4_167046402051906.xml · derivative · entry 3 Sherman Jeffrey Scott · CIK 0001463145 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 249,169 Underlying: Common Stock · 249,169 shares Expires 2029-12-05 F3 · derivative.exercise_date: On December 5, 2022, Mr. Sherman was granted 249,169 stock options. These awards vest ratably over four years with the first tranche vesting on December 7, 2023. Read SEC document
December 05, 2022 Filed Dec 8, 2022 01:47 UTC	NEOGENOMICS INC NEO · Entity 2096	GrantCommon Stock	89,206	$0.00	$0.00	Disclosure SEC source: 0001077183-22-000202 · wf-form4_167046402051906.xml · nonDerivative · entry 2 Sherman Jeffrey Scott · CIK 0001463145 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,809 F2 · kind: On December 5, 2022, Mr. Sherman was granted an award of 89,206 shares of restricted stock. The shares subject to this award shall vest upon the achievement of an absolute total stockholder return of at least 20% for the period commencing December 7, 2022 and ending December 6, 2023. If such vesting condition is met, the shares subject to the award shall vest ratably over four years with the first tranche vesting on December 7, 2023. Read SEC document
December 05, 2022 Filed Dec 8, 2022 01:47 UTC	NEOGENOMICS INC NEO · Entity 2096	GrantCommon Stock	44,603	$0.00	$0.00	Disclosure SEC source: 0001077183-22-000202 · wf-form4_167046402051906.xml · nonDerivative · entry 1 Sherman Jeffrey Scott · CIK 0001463145 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,603 F1 · kind: On December 5, 2022, Mr. Sherman was granted an award of 44,603 shares of restricted stock. The shares subject to this award shall vest ratably over four years with the first tranche vesting on December 7, 2023. Read SEC document
January 05, 2022 Filed Jan 7, 2022 22:20 UTC	Privia Health Group, Inc. PRVA · Entity 1532	GrantStock Option (Right to Purchase) · Derivative	235,128	$0.00 Strike: $25.69	$0.00	Disclosure SEC source: 0001759655-22-000009 · wf-form4_164159402168915.xml · derivative · entry 2 Sherman Jeffrey Scott · CIK 0001463145 · EVP, CFO and CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 235,128 Underlying: Common Stock · 235,128 shares Expires 2032-01-05 F2 · derivative.exercise_date: Represents options granted under the Issuer's 2021 Omnibus Incentive Plan that will vest in substantially equal annual installments on the first, second, third and fourth anniversaries of the grant date. Read SEC document
January 05, 2022 Filed Jan 7, 2022 22:20 UTC	Privia Health Group, Inc. PRVA · Entity 1532	GrantCommon Stock, $0.01 par value per share	61,307	$0.00	$0.00	Disclosure SEC source: 0001759655-22-000009 · wf-form4_164159402168915.xml · nonDerivative · entry 1 Sherman Jeffrey Scott · CIK 0001463145 · EVP, CFO and CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,307 F1 · security: Represents restricted stock units granted under the Issuer's 2021 Omnibus Incentive Plan that will vest in substantially equal annual installments on the first, second, third and fourth anniversaries of the grant date. Read SEC document
April 01, 2021 Filed Apr 1, 2021 21:19 UTC	HMS HOLDINGS CORP HMSY · Entity 140668	Disposition to issuerStock Option (Right to Buy) · Derivative	65,265	Not disclosed Strike: $39.63	Not disclosed	Disclosure SEC source: 0001104659-21-045694 · tm2111522-13_4seq1.xml · derivative · entry 6 Sherman Jeffrey Scott · CIK 0001463145 · EVP, CFO, and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 65,265 shares Expires 2029-02-28 F3 · price: Pursuant to the procedures set forth in the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock with a per share exercise price that is equal or greater than the Per Share Merger Consideration, whether vested or unvested, was cancelled for no consideration. F3 · derivative.exercise_date: Pursuant to the procedures set forth in the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock with a per share exercise price that is equal or greater than the Per Share Merger Consideration, whether vested or unvested, was cancelled for no consideration. Read SEC document
April 01, 2021 Filed Apr 1, 2021 21:19 UTC	HMS HOLDINGS CORP HMSY · Entity 140668	Disposition to issuerStock Option (Right to Buy) · Derivative	112,360	Not disclosed Strike: $27.34	Not disclosed	Disclosure SEC source: 0001104659-21-045694 · tm2111522-13_4seq1.xml · derivative · entry 5 Sherman Jeffrey Scott · CIK 0001463145 · EVP, CFO, and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 112,360 shares Expires 2030-02-27 F2 · price: Pursuant to the procedures set forth in the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock with a per share exercise price that is less than the Per Share Merger Consideration that is outstanding and unexercised, was cancelled and converted into the right to receive a cash payment equal to the product of (x) the Per Share Merger Consideration, net of the applicable per share exercise price and (y) the aggregate number of shares of Common Stock subject to the option, less applicable withholding taxes or other amounts required by law. F2 · derivative.exercise_date: Pursuant to the procedures set forth in the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock with a per share exercise price that is less than the Per Share Merger Consideration that is outstanding and unexercised, was cancelled and converted into the right to receive a cash payment equal to the product of (x) the Per Share Merger Consideration, net of the applicable per share exercise price and (y) the aggregate number of shares of Common Stock subject to the option, less applicable withholding taxes or other amounts required by law. Read SEC document
April 01, 2021 Filed Apr 1, 2021 21:19 UTC	HMS HOLDINGS CORP HMSY · Entity 140668	Disposition to issuerStock Option (Right to Buy) · Derivative	117,130	Not disclosed Strike: $19.48	Not disclosed	Disclosure SEC source: 0001104659-21-045694 · tm2111522-13_4seq1.xml · derivative · entry 4 Sherman Jeffrey Scott · CIK 0001463145 · EVP, CFO, and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 117,130 shares Expires 2028-03-02 F2 · price: Pursuant to the procedures set forth in the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock with a per share exercise price that is less than the Per Share Merger Consideration that is outstanding and unexercised, was cancelled and converted into the right to receive a cash payment equal to the product of (x) the Per Share Merger Consideration, net of the applicable per share exercise price and (y) the aggregate number of shares of Common Stock subject to the option, less applicable withholding taxes or other amounts required by law. F2 · derivative.exercise_date: Pursuant to the procedures set forth in the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock with a per share exercise price that is less than the Per Share Merger Consideration that is outstanding and unexercised, was cancelled and converted into the right to receive a cash payment equal to the product of (x) the Per Share Merger Consideration, net of the applicable per share exercise price and (y) the aggregate number of shares of Common Stock subject to the option, less applicable withholding taxes or other amounts required by law. Read SEC document
April 01, 2021 Filed Apr 1, 2021 21:19 UTC	HMS HOLDINGS CORP HMSY · Entity 140668	Disposition to issuerStock Option (Right to Buy) · Derivative	109,961	Not disclosed Strike: $19.04	Not disclosed	Disclosure SEC source: 0001104659-21-045694 · tm2111522-13_4seq1.xml · derivative · entry 3 Sherman Jeffrey Scott · CIK 0001463145 · EVP, CFO, and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 109,961 shares Expires 2027-06-09 F2 · price: Pursuant to the procedures set forth in the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock with a per share exercise price that is less than the Per Share Merger Consideration that is outstanding and unexercised, was cancelled and converted into the right to receive a cash payment equal to the product of (x) the Per Share Merger Consideration, net of the applicable per share exercise price and (y) the aggregate number of shares of Common Stock subject to the option, less applicable withholding taxes or other amounts required by law. F2 · derivative.exercise_date: Pursuant to the procedures set forth in the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock with a per share exercise price that is less than the Per Share Merger Consideration that is outstanding and unexercised, was cancelled and converted into the right to receive a cash payment equal to the product of (x) the Per Share Merger Consideration, net of the applicable per share exercise price and (y) the aggregate number of shares of Common Stock subject to the option, less applicable withholding taxes or other amounts required by law. Read SEC document
April 01, 2021 Filed Apr 1, 2021 21:19 UTC	HMS HOLDINGS CORP HMSY · Entity 140668	Disposition to issuerCommon Stock	10,760	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-21-045694 · tm2111522-13_4seq1.xml · nonDerivative · entry 2 Sherman Jeffrey Scott · CIK 0001463145 · EVP, CFO, and Treasurer 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Trust Disclosed balance after: 0 F1 · price: On April 1, 2021, pursuant to that certain Agreement and Plan of Merger, dated as of December 20, 2020 (the "Merger Agreement"), by and among the Issuer, Gainwell Acquisition Corp. ("Gainwell"), Mustang Merger Sub, Inc. ("Merger Sub") and Gainwell Intermediate Holding Corp., Merger Sub merged with and into the Issuer with the Issuer surviving as a wholly owned subsidiary of IRC (the "Merger"). Upon consummation of the Merger (the "Effective Time"), each share of common stock of the Issuer was cancelled and converted into the right to receive $37.00 per share in cash (the "Per Share Merger Consideration"). In addition, each unvested restricted stock unit automatically vested and was converted in the right to receive the Per Share Merger Consideration. Read SEC document
April 01, 2021 Filed Apr 1, 2021 21:19 UTC	HMS HOLDINGS CORP HMSY · Entity 140668	Disposition to issuerCommon Stock	200,630	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-21-045694 · tm2111522-13_4seq1.xml · nonDerivative · entry 1 Sherman Jeffrey Scott · CIK 0001463145 · EVP, CFO, and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: On April 1, 2021, pursuant to that certain Agreement and Plan of Merger, dated as of December 20, 2020 (the "Merger Agreement"), by and among the Issuer, Gainwell Acquisition Corp. ("Gainwell"), Mustang Merger Sub, Inc. ("Merger Sub") and Gainwell Intermediate Holding Corp., Merger Sub merged with and into the Issuer with the Issuer surviving as a wholly owned subsidiary of IRC (the "Merger"). Upon consummation of the Merger (the "Effective Time"), each share of common stock of the Issuer was cancelled and converted into the right to receive $37.00 per share in cash (the "Per Share Merger Consideration"). In addition, each unvested restricted stock unit automatically vested and was converted in the right to receive the Per Share Merger Consideration. Read SEC document
March 02, 2021 Filed Mar 4, 2021 22:00 UTC	HMS HOLDINGS CORP HMSY · Entity 140668	Tax withholdingCommon Stock	3,906	$36.81	$143,779.86	Disclosure SEC source: 0001225208-21-004722 · doc4.xml · nonDerivative · entry 1 Sherman Jeffrey Scott · CIK 0001463145 · EVP, CFO, and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,630 Read SEC document
February 28, 2021 Filed Mar 2, 2021 22:42 UTC	HMS HOLDINGS CORP HMSY · Entity 140668	Tax withholdingCommon Stock	2,120	$36.79	$77,994.80	Disclosure SEC source: 0001225208-21-004310 · doc4.xml · nonDerivative · entry 2 Sherman Jeffrey Scott · CIK 0001463145 · EVP, CFO, and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 204,536 Read SEC document
February 27, 2021 Filed Mar 2, 2021 22:42 UTC	HMS HOLDINGS CORP HMSY · Entity 140668	Tax withholdingCommon Stock	3,547	$36.79	$130,494.13	Disclosure SEC source: 0001225208-21-004310 · doc4.xml · nonDerivative · entry 1 Sherman Jeffrey Scott · CIK 0001463145 · EVP, CFO, and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 206,656 Read SEC document
March 03, 2020 Filed Mar 4, 2020 21:46 UTC	HMS HOLDINGS CORP HMSY · Entity 140668	Tax withholdingCommon Stock	3,624	$22.76	$82,482.24	Disclosure SEC source: 0001225208-20-004350 · doc4.xml · nonDerivative · entry 2 Sherman Jeffrey Scott · CIK 0001463145 · EVP, CFO, and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,203 F1 · shares: The reported shares were withheld by the Issuer to satisfy tax withholding obligations upon the vesting of a portion of the Reporting Person's restricted stock units. Read SEC document
March 02, 2020 Filed Mar 4, 2020 21:46 UTC	HMS HOLDINGS CORP HMSY · Entity 140668	Tax withholdingCommon Stock	3,834	$23.98	$91,939.32	Disclosure SEC source: 0001225208-20-004350 · doc4.xml · nonDerivative · entry 1 Sherman Jeffrey Scott · CIK 0001463145 · EVP, CFO, and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 213,827 F1 · shares: The reported shares were withheld by the Issuer to satisfy tax withholding obligations upon the vesting of a portion of the Reporting Person's restricted stock units. Read SEC document
February 29, 2020 Filed Mar 2, 2020 21:45 UTC	HMS HOLDINGS CORP HMSY · Entity 140668	Tax withholdingCommon Stock	2,174	$22.97	$49,936.78	Disclosure SEC source: 0001225208-20-003893 · doc4.xml · nonDerivative · entry 2 Sherman Jeffrey Scott · CIK 0001463145 · EVP, CFO, and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 217,661 F1 · shares: The reported shares were withheld by the Issuer to satisfy tax withholding obligations upon the vesting of a portion of the Reporting Person's restricted stock units. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.